Sign inJoin waitlistJoin the waitlist

Karen Rabin

Director, Leukemia Program · Baylor College of Medicine

Credentials: · · · ·

History

University of California (San Francisco) School of Medicine
Present
St Jude Children's Research Hospital
Present
Baylor College of Medicine
Present

Pediatrics
Kings College
University of California, San Francisco School of Medicine
Harvard University

Research

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Nature Genetics · 2019 · 494 citations
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia
Nature Genetics · 2009 · Last of 24 authors · 466 citations
The genomic landscape of pediatric acute lymphoblastic leukemia
Nature Genetics · 2022 · 338 citations

Mignon Loh
39 papers
Elizabeth Raetz
35 papers
Stephen Hunger
35 papers
Brent Wood
28 papers
Monica Gramatges
28 papers
William Carroll
26 papers
Naomi Winick
22 papers
MB
Michael Borowitz
20 papers
Patrick Zweidler-McKay
19 papers
AA
Anne Angiolillo
15 papers
David Teachey
15 papers
Michael Burke
15 papers

Grants

Reducing Disparities in Acute Leukemia (REDIAL) Consortium
National Cancer Institute · U54
PI · $4.9M · Baylor College of Medicine
2025–2030
Down Syndrome Early Childhood Omics, Deep Phenotyping, and Epidemiology in Texas: DECODE IT Cohort
National Institute of Child Health and Human Development · U01
PI · $4.4M · Emory University
2024–2029
Preventing Fatal Infections in Children with Down Syndrome During Treatment for Acute Lymphoblastic Leukemia
National Cancer Institute · R01
PI · $1.6M · Columbia University Health Sciences
2024–2029
Chronic Health Conditions in Survivors of Down Syndrome-Associated Leukemia
National Cancer Institute · R01
PI · $3.1M · Baylor College of Medicine
2022–2028

Clinical trials

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Principal investigator · Completed
Children's Oncology Group
2010–2023
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Site PI · Recruiting
Children's Oncology Group
2023–2029
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2020–2028